4DMedical Advances U.S. Adoption of CT:VQ™ at Leading Medical Centres
4DMedical Limited (ASX: 4DX) operates as an international medical technology innovator, dedicated to advancing respiratory healthcare through the application of sophisticated imaging solutions and artificial intelligence–driven insights. Its patented XV Technology® converts standard CT scans into detailed functional insights, enabling earlier and more precise diagnosis and monitoring of lung disease. The company’s flagship CT:VQ™ solution integrates ventilation and perfusion analysis and is positioned as an alternative to traditional nuclear VQ imaging.
Following recent FDA clearance, CT:VQ™ has achieved rapid commercial traction in the United States, with adoption by Cleveland Clinic, Stanford University, and the University of Miami within a three-month period. Cleveland Clinic’s deployment is particularly significant, given its global reputation and influence, and is expected to act as a key reference site for broader market penetration.
Delivered via a SaaS model and supported by AI capabilities strengthened through the Imbio acquisition, 4DMedical is executing a focused commercialisation strategy aimed at establishing CT:VQ™ as a new standard of care in respiratory diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
4DMedical Advances U.S. Adoption of CT:VQ™ at Leading Medical Centres
4DMedical Limited (ASX: 4DX) operates as an international medical technology innovator, dedicated to advancing respiratory healthcare through the application of sophisticated imaging solutions and artificial intelligence–driven insights. Its patented XV Technology® converts standard CT scans into detailed functional insights, enabling earlier and more precise diagnosis and monitoring of lung disease. The company’s flagship CT:VQ™ solution integrates ventilation and perfusion analysis and is positioned as an alternative to traditional nuclear VQ imaging.
Following recent FDA clearance, CT:VQ™ has achieved rapid commercial traction in the United States, with adoption by Cleveland Clinic, Stanford University, and the University of Miami within a three-month period. Cleveland Clinic’s deployment is particularly significant, given its global reputation and influence, and is expected to act as a key reference site for broader market penetration.
Delivered via a SaaS model and supported by AI capabilities strengthened through the Imbio acquisition, 4DMedical is executing a focused commercialisation strategy aimed at establishing CT:VQ™ as a new standard of care in respiratory diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au